Format

Send to

Choose Destination
MAbs. 2014 May-Jun;6(3):577-618. doi: 10.4161/mabs.28421. Epub 2014 Mar 3.

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Author information

1
CTI-Boston, Pfizer; Boston, MA USA.
2
Janssen Research & Development, LLC; Spring House, PA USA.
3
Simon Fraser University; Burnaby, BC CA.
4
The Scripps Research Institute; La Jolla, CA USA.
5
Reichert Biotechnology Consulting, LLC; Framingham, MA USA.
6
CONICET; Laboratorio Biotecnología Farmacéutica; Instituto de Biología y Medicina Experimental, IBYME; Ciudad Autónoma de Buenos Aires, Argentina.
7
Adimab, LLC; Lebanon, NH USA.
8
Innate Pharma; Marseille, France.
9
Regeneron Pharmaceuticals, Inc.; Tarrytown, NY USA.
10
Amgen, Thousand Oaks, CA, USA.
11
AbbVie; Ludwigshafen, Germany.
12
Tel Aviv University, Tel Aviv, Israel.
13
Vanderbilt University Medical Center, Nashville, TN, USA.
14
Huston BioConsulting, LLC; Newton, MA, USA.
15
Arizona State University; Phoenix, AZ USA.
16
Oslo University Hospital; Oslo, Norway.
17
Dana-Farber Cancer Center; Boston, MA USA.
18
Genmab; Utrecht, The Netherlands.
19
University of Maryland; Baltimore, MD USA.

Abstract

The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; antibody deep sequencing and repertoires; the effects of antibody gene variation and usage on antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; antibody pharmacokinetics, distribution and off-target toxicity; optimizing antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; antibody discovery platforms; and antibody-drug conjugates.

KEYWORDS:

antibody therapeutics,; antibody-drug conjugate; bispecific antibodies; protein scaffolds

PMID:
24589717
PMCID:
PMC4011904
DOI:
10.4161/mabs.28421
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center